Ildong Pharmaceutical announced plans to reapply for marketing authorization of the oral antiviral Covid-19 treatment, Ensitrelvir fumaric acid, after strengthening its clinical data.

Ildong Pharmaceutical to refile approval application for oral Covid-19 treatment

Those who qualify can get subsidies of up to 75 per cent from November 2024.

Enough Paxlovid to treat Covid-19 in at-risk adults, but it is no longer free: MOH

Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).

Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?

Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19.

Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults

Sunshine Biopharma Inc. announced it has developed an orally active protease inhibitor that showed dose-dependent antiviral activity in mice infected with SARS-CoV-2.

Sunshine Biopharma’s PLpro inhibitor shows activity in SARS-CoV-2

The effectiveness of remdesivir was consistent among patients who received any form of supplemental oxygen and across all age groups in the study.

antiviral news

Press Releases in the global landscape